top of page

FDA Investigating Serious Risk of T-cell Malignancy

  • Nov 30, 2023
  • 1 min read

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies


 
 
bottom of page